Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Erdafitinib in Recurrent FGFR3-Altered NMIBC
NCT04917809Phase 2Active, not recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Feb 2022
- Primary completion
- Aug 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of erdafitinib in bladder cancer, sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Objective response rate at 3 weeks. Started Feb 2022; status: active, not recruiting.
02
Drugs
erdafitinib
03
Conditions
bladder cancer
Beyond the preview
Go deeper on NCT04917809.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04917809.